Granules eyes foray into peptide segment, CDMO business with ₹192 cr. acquisition of Swiss firm
With this acquisition, Granules will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the growing demand for Amino Acid Derivative, and more
With this acquisition, Granules will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the growing demand for Amino Acid Derivative, and more
What's Your Reaction?
